Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03964233
Title	A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Boehringer Ingelheim
Indications	lung non-small cell carcinoma gastric adenocarcinoma dedifferentiated liposarcoma leiomyosarcoma transitional cell carcinoma biliary tract cancer hepatocellular carcinoma synovial sarcoma Advanced Solid Tumor liposarcoma myxofibrosarcoma
Therapies	BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| HUN \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS